DALLAS, March 16, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotech company StemCells Inc. (Nasdaq:STEM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.beaconequity.com/i/STEM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
StemCells Inc. (STEM) is a biopharmaceutical company engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell, and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders.
Message Board Search for STEM: http://www.boardcentral.com/boards/STEM
In the report, the analyst notes:
"STEM recently posted its fourth-quarter results, gaining revenue from its acquisition of Stem Cell Sciences PLC in April in a cash and stock deal. In the fourth quarter, STEM said it lost $5.2 million, or $(0.05) per share. A year ago, the Company posted a loss of $10.1 million, or $(0.011) per share. Its revenue more than doubled to $418,000 from $172,000.
"In February the Company announced the launch of GS2-M(TM), a new cell culture medium that enables the derivation and long-term maintenance of true (germline competent) mouse induced pluripotent stem (iPS) cells. GS2-M is part of the Company's growing SC Proven(R) line of specialty cell culture products."
To read the entire report visit: http://www.beaconequity.com/i/STEM
See what investors are saying about STEM at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com.
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.